Biz Blog

Choose a blog

Icagen ready to abandon experimental asthma drug

Bookmark and Share

Icagen, a small Durham-based drug development company, will likely stop work on an experimental asthma treatment after reporting disappointing clinical results.

The company's shares slumped as much as 35 percent.

A study of 69 patients showed that the experimental asthma drug senicapoc failed to ease symptoms of exercise-induced asthma. Icagen CEO P. Kay Wagoner said that the company will focus resources on its leading drug candidate, which is being tested as a treatment for epilepsy and pain.

Icagen also is working with its largest investor and partner, drug maker Pfizer, on new treatments for pain.

Icagen's stock fell 29 cents to 48 cents today.

Cars View All
Find a Car
Jobs View All
Find a Job
Homes View All
Find a Home

Want to post a comment?

In order to join the conversation, you must be a member of Click here to register or to log in.

About the blogger

Assistant Business Editor Alan M. Wolf joined the N&O in 1999 covering the business of health care. He became an editor in 2001, and helps oversee the paper's daily business coverage and Sunday Work&Money section. He lives in Clayton with his wife and two children. Reach him at 919-829-4572 or e-mail him.